Literature DB >> 20002210

Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation.

Urban Svajger1, Natasa Obermajer, Matjaz Jeras.   

Abstract

Resveratrol is a polyphenol that acts on multiple molecular targets important for cell differentiation and activation. Dendritic cells (DCs) are a functionally diverse cell type and represent the most potent antigen-presenting cells of the immune system. In this study, we investigated resveratrol-induced effects on DCs during their differentiation and maturation. Our results show that resveratrol induces DC-associated tolerance, particularly when applied during DC differentiation. Costimulatory molecules CD40, CD80 and CD86 were down-regulated, as was the expression of major histocompatibility complex (MHC) class II molecules. Surface expression of inhibitory immunoglobulin-like transcript 3 (ILT3) and ILT4 molecules was induced, while human leucocyte antigen (HLA)-G expression was not affected. Resveratrol-treated DCs lost the ability to produce interleukin (IL)-12p70 after activation, but had an increased ability to produce IL-10. Such DCs were poor stimulators of allogeneic T cells and had lowered ability to induce CD4(+) T-cell migration. Furthermore, treated cells were able to generate allogeneic IL-10-secreting T cells, but were not competent in inducing FoxP3 expression These tolerogenic effects are probably associated with the effect of resveratrol on multiple molecular targets through which it interferes with DC differentiation and nuclear factor (NF)-kappaB translocation. Our data provide new insights into the molecular and functional mechanisms of the tolerogenic effects that resveratrol exerts on DCs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20002210      PMCID: PMC2842499          DOI: 10.1111/j.1365-2567.2009.03205.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  41 in total

1.  Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway.

Authors:  D Koul; Y Yao; J L Abbruzzese; W K Yung; S A Reddy
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

Review 2.  Dendritic cells: emerging pharmacological targets of immunosuppressive drugs.

Authors:  Holger Hackstein; Angus W Thomson
Journal:  Nat Rev Immunol       Date:  2004-01       Impact factor: 53.106

3.  Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?

Authors:  Manfred B Lutz; Gerold Schuler
Journal:  Trends Immunol       Date:  2002-09       Impact factor: 16.687

4.  Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells.

Authors:  Zeev Estrov; Shishir Shishodia; Stefan Faderl; David Harris; Quin Van; Hagop M Kantarjian; Moshe Talpaz; Bharat B Aggarwal
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

5.  Configuration of human dendritic cell cytoskeleton by Rho GTPases, the WAS protein, and differentiation.

Authors:  S Burns; A J Thrasher; M P Blundell; L Machesky; G E Jones
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

6.  Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4.

Authors:  C C Chang; R Ciubotariu; J S Manavalan; J Yuan; A I Colovai; F Piazza; S Lederman; M Colonna; R Cortesini; R Dalla-Favera; N Suciu-Foca
Journal:  Nat Immunol       Date:  2002-01-28       Impact factor: 25.606

7.  Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells.

Authors:  Jin Xie; Ying Wang; Muta E Freeman; Bart Barlogie; Qing Yi
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

8.  Cutting edge: in vitro-generated tolerogenic APC induce CD8+ T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis.

Authors:  Douglas E Faunce; Ania Terajewicz; Joan Stein-Streilein
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

9.  Interleukin-10 induces the upregulation of the inhibitory receptor ILT4 in monocytes from HIV positive individuals.

Authors:  George Vlad; Flavia Piazza; Adriana Colovai; Raffaello Cortesini; Fatima Della Pietra; Nicole Suciu-Foca; John S Manavalan
Journal:  Hum Immunol       Date:  2003-05       Impact factor: 2.850

10.  Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells.

Authors:  Katsuaki Sato; Naohide Yamashita; Masanori Baba; Takami Matsuyama
Journal:  Blood       Date:  2003-01-02       Impact factor: 22.113

View more
  26 in total

Review 1.  Dietary agents in cancer prevention: an immunological perspective.

Authors:  Ya Ying Zheng; Bharathi Viswanathan; Pravin Kesarwani; Shikhar Mehrotra
Journal:  Photochem Photobiol       Date:  2012-03-30       Impact factor: 3.421

Review 2.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

Review 3.  The bioenergetics of inflammation: insights into obesity and type 2 diabetes.

Authors:  K N Keane; E K Calton; R Carlessi; P H Hart; P Newsholme
Journal:  Eur J Clin Nutr       Date:  2017-04-12       Impact factor: 4.016

4.  Resveratrol (3, 5, 4'-Trihydroxy-trans-Stilbene) Attenuates a Mouse Model of Multiple Sclerosis by Altering the miR-124/Sphingosine Kinase 1 Axis in Encephalitogenic T Cells in the Brain.

Authors:  K Alexa Orr Gandy; Jiajia Zhang; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  J Neuroimmune Pharmacol       Date:  2019-04-02       Impact factor: 4.147

Review 5.  Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors.

Authors:  T Hahn; M J Polanczyk; A Borodovsky; L V Ramanathapuram; E T Akporiaye; S J Ralph
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

Review 6.  Dendritic cell metabolism.

Authors:  Edward J Pearce; Bart Everts
Journal:  Nat Rev Immunol       Date:  2015-01       Impact factor: 53.106

Review 7.  Myeloid Cell-Derived Oxidized Lipids and Regulation of the Tumor Microenvironment.

Authors:  Kristin C Hicks; Yulia Y Tyurina; Valerian E Kagan; Dmitry I Gabrilovich
Journal:  Cancer Res       Date:  2021-11-11       Impact factor: 13.312

8.  Effects of freeze-dried cranberry powder on serum lipids and inflammatory markers in lipopolysaccharide treated rats fed an atherogenic diet.

Authors:  Mi Joung Kim; Jeong Ohn; Jung Hee Kim; Ho-Kyung Kwak
Journal:  Nutr Res Pract       Date:  2011-10-28       Impact factor: 1.926

9.  GRAS-microparticle microarrays identify dendritic cell tolerogenic marker-inducing formulations.

Authors:  Matthew R Carstens; Clive H Wasserfall; Abhinav P Acharya; Jamal Lewis; Nikunj Agrawal; Kevin Koenders; Evelyn Bracho-Sanchez; Benjamin G Keselowsky
Journal:  Lab Chip       Date:  2021-09-14       Impact factor: 7.517

10.  Resveratrol prevents dendritic cell maturation in response to advanced glycation end products.

Authors:  Brigitta Buttari; Elisabetta Profumo; Francesco Facchiano; Elif Inci Ozturk; Luca Segoni; Luciano Saso; Rachele Riganò
Journal:  Oxid Med Cell Longev       Date:  2013-07-09       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.